These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 16777686

  • 1. Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: combination therapy using paclitaxel and IL-12.
    Pressley JS, Elgert KD.
    Cancer Invest; 2006; 24(4):351-9. PubMed ID: 16777686
    [Abstract] [Full Text] [Related]

  • 2. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation.
    Mullins DW, Koci MD, Burger CJ, Elgert KD.
    Immunopharmacol Immunotoxicol; 1998 Nov; 20(4):473-92. PubMed ID: 9805229
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Enhancement of antitumor effects of paclitaxel (taxol) in combination with red ginseng acidic polysaccharide (RGAP).
    Shin HJ, Kim YS, Kwak YS, Song YB, Kim YS, Park JD.
    Planta Med; 2004 Nov; 70(11):1033-8. PubMed ID: 15549658
    [Abstract] [Full Text] [Related]

  • 5. Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation.
    Mullins DW, Martins RS, Burger CJ, Elgert KD.
    J Leukoc Biol; 2001 Jan; 69(1):129-37. PubMed ID: 11200057
    [Abstract] [Full Text] [Related]

  • 6. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 1):644-53. PubMed ID: 17255288
    [Abstract] [Full Text] [Related]

  • 7. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
    Latimer P, Menchaca M, Snyder RM, Yu W, Gilbert BE, Sanders BG, Kline K.
    Exp Biol Med (Maywood); 2009 Oct 15; 234(10):1244-52. PubMed ID: 19657067
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities.
    Mullins DW, Walker TM, Burger CJ, Elgert KD.
    Cancer Immunol Immunother; 1997 Oct 15; 45(1):20-8. PubMed ID: 9353423
    [Abstract] [Full Text] [Related]

  • 12. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
    Patil Y, Sadhukha T, Ma L, Panyam J.
    J Control Release; 2009 May 21; 136(1):21-9. PubMed ID: 19331851
    [Abstract] [Full Text] [Related]

  • 13. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [Abstract] [Full Text] [Related]

  • 14. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
    Jung U, Foley JE, Erdmann AA, Toda Y, Borenstein T, Mariotti J, Fowler DH.
    Biol Blood Marrow Transplant; 2006 Sep 01; 12(9):905-18. PubMed ID: 16920556
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ethanol consumption modifies dendritic cell antigen presentation in mice.
    Heinz R, Waltenbaugh C.
    Alcohol Clin Exp Res; 2007 Oct 01; 31(10):1759-71. PubMed ID: 17850646
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
    Balkow S, Loser K, Krummen M, Higuchi T, Rothoeft T, Apelt J, Tuettenberg A, Weishaupt C, Beissert S, Grabbe S.
    Exp Dermatol; 2009 Jan 01; 18(1):78-87. PubMed ID: 19054060
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors.
    Hoffmann D, Bayer W, Wildner O.
    Int J Mol Med; 2007 Nov 01; 20(5):673-81. PubMed ID: 17912460
    [Abstract] [Full Text] [Related]

  • 20. Ex vivo activated OVA specific and non-specific CD4+CD25+ regulatory T cells exhibit comparable suppression to OVA mediated T cell responses.
    Li J, Bracht M, Shang X, Radewonuk J, Emmell E, Griswold DE, Li L.
    Cell Immunol; 2006 Jun 01; 241(2):75-84. PubMed ID: 17010326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.